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Abstract
Background: We have recently demonstrated that modulation of the gap junction protein, connexin43, can affect
the response of osteoblasts to fibroblast growth factor 2 in a protein kinase C-delta-dependent manner. Others
have shown that the C-terminal tail of connexin43 serves as a docking platform for signaling complexes. It is
unknown whether protein kinase C-delta can physically interact with connexin43.
Results: In the present study, we investigate by immunofluorescent co-detection and biochemical examination the
interaction between Cx43 and protein kinase C-delta. We establish that protein kinase C-delta physically interacts
with connexin43 during fibroblast growth factor 2 signaling, and that protein kinase C delta preferentially co-
precipitates phosphorylated connexin43. Further, we show by pull down assay that protein kinase C-delta
associates with the C-terminal tail of connexin43.
Conclusions: Connexin43 can serve as a direct docking platform for the recruitment of protein kinase C-delta in
order to affect fibroblast growth factor 2 signaling in osteoblasts. These data expand the list of signal molecules
that assemble on the connexin43 C-terminal tail and provide a critical context to understand how gap junctions
modify signal transduction cascades in order to impact cell function.
Background
Gap junctions are transcellular channels formed by the
juxtaposition of two hemichannels, each composed of
six connexin monomers, present on adjacent cells. The
assembled gap junctions then aggregate to form gap
junction plaques. Gap junctional communication main-
tains metabolic continuity between cells and mediates
the rapid and efficient transmission of small molecules,
including second messengers among the interconnected
cells.
Connexin43 (Cx43) is the principal gap junction pro-
tein expressed in osteoblasts and osteocytes, where it
has been implicated in transmitting hormonal, mechani-
cal load and growth factor induced signals [1,2]. Muta-
tion of connexins has been implicated in several
diseases [3-5]. Point mutations in GJA1, the gene encod-
ing the gap junction protein Cx43, result in the human
pleiotropic disorder oculodentodigital dysplasia, which
includes skeletal manifestations [6]. Mouse models of
oculodentodigital dysplasia [7,8] and Cx43 genetic
ablation [9-11] have underscored the importance of
Cx43 in skeletal function. However, little is known
about the molecular mechanisms by which gap junctions
regulate the function of skeletal tissues.
Using osteoblast cell lines, we have demonstrated that
Cx43 can modulate growth factor responses and signal
transduction cascades, leading to altered gene expression
and osteoblast function [12-14]. We have recently
reported that modulation of Cx43 can affect signal
transduction in response to fibroblast growth factor 2
(FGF2) in a protein kinase C-delta (PKCδ)-dependent
manner in osteoblasts [14]. PKCδ is a member of the
novel PKCs, which, unlike classic PKCs, are calcium-
independent but are activated by diacylglycerol and
phosphatidylserine. In a previous study, we demon-
strated that overexpression of Cx43 in a mouse osteo-
blast cell line could enhance the transcriptional
response of the osteocalcin gene promoter to FGF2
treatment; an effect that could be abrogated by inhibi-
tion of PKCδ expression or activity [14]. Conversely,
inhibition of Cx43 expression could attenuate the ability
of these cells to respond to FGF2. From these data, we
hypothesize that Cx43 may recruit PKCδ locally to the
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messengers being propagated through the gap junction
channel. Indeed, numerous studies have shown that
Cx43 can serve as a docking platform for signal com-
plexes, including b-catenin, src, PKCa and PKCε
[15-18]. The novel PKC family member, PKCδ,h a sn o t
been shown to interact with Cx43. Accordingly, we set
out to examine the biochemical interactions between
Cx43 and PKCδ as it relates to the effects of FGF2 sig-
naling. By understanding these biochemical interactions,
we gain insight into the biologically relevant signals that
may be propagated through gap junction channels as
well as a greater understanding of how gap junctions
regulate signal transduction cascades and, ultimately,
cell function.
Results
PKCδ-dependent phosphorylation of Cx43
Whole cell extracts were prepared from MC3T3 osteo-
blasts following treatment with vehicle (phosphate buf-
fered saline, 0.1% bovine serum albumin, 1 mM
dithiothreitol), FGF2 (5 ng/ml) or phorbol 12-myristate
13-acetate (PMA, 200 nM) for up to 30 minutes. Wes-
tern blots probed with anti-phospho-PKCδ (Thr505)
antibodies reveal that treatment with FGF2 (5 ng/ml)
increases the phosphorylation of PKCδ by 5 minutes,
increasing further by 30 minutes (Figure 1A). Antibodies
against phospho-Cx43 (Ser368) reveal that FGF2 treat-
ment induces a concomitant phosphorylation of Cx43 at
serine 368, a known target of PKC-mediated phosphory-
lation (Figure 1A). We observe similar results with PMA
treatments, a positive control for PKC phosphorylation
at threonine 505 and Cx43 phosphorylation at serine
368 [19]. Pre-treatment of MC3T3 cells with the PKCδ
inhibitor rottlerin (3 and 5 μM) prevents the FGF2-
induced phosphorylation of Cx43 at serine 368 (Figure
1B). This suggests that PKCδ phosphorylates Cx43 and
that the two proteins physically interact, at least transi-
ently, during FGF2 treatment.
Immunofluorescent detection of PKCδ and Cx43
In order to examine the subcellular localization of acti-
vated PKCδ, MC3T3 cells treated with vehicle or 5 ng/
ml FGF2, for the indicated times, were fixed and stained
with anti-phospho-PKCδ (Thr505) antibodies (Figure
2A). By immunofluorescence microscopy, we examined
the localization of phospho-PKCδ (Thr505) in osteo-
blasts over a time course following exposure to FGF2.
W h i l ec l a s s i cP K C sa r er a p i d l yt r a n s l o c a t e dt ot h e
plasma membrane upon activation, PKCδ has been
shown to translocate not only to the plasma membrane
but also to the nucleus [20,21]. Prior to treatment with
FGF2 (Figure 2A, 0 min), phospho-PKCδ is detected dif-
fusely throughout the cytoplasm and in defined foci in
the nuclei. Occasional, weak staining is observed at the
periphery of cells. In contrast, within 10 minutes of
exposure to FGF2, there is a rapid accumulation of
phospho-PKCδ staining observed in the nuclear com-
partment (Figure 2A, 10 min). Interestingly, we did not
see a generalized staining of the plasma membrane with
anti-phospho-PKCδ antibodies, rather we noticed a dis-
tinct pattern of staining near the point of cell-cell con-
tacts, that is remindful of the staining we see for Cx43
in these cells. The apparent accumulation of phospho-
PKCδ staining at cell-cell contacts remained at 20 min-
utes following FGF2 stimulation (Figure 2A, 20 min). To
determine if PKCδ is accumulating at the plasma mem-
brane, we prepared protein extracts on plasma mem-
brane preparations from osteoblasts during a time
course of FGF2 treatment. Subsequent, western blots of
these plasma membrane extracts were probed with anti-
PKCδ, anti-phospho-PKCδ (Thr505) and anti-Cx43 anti-
bodies. There is a notable accumulation of PKCδ and
phospho-PKCδ in the membrane protein extract follow-
ing treatment with FGF2 for 5 minutes (Figure 2B). This
accumulation at the plasma membrane is transient,
however, as it begins to diminish 30 minutes after FGF2
administration. Cx43 levels in the membrane fraction
remain relatively static (Figure 2B). Importantly, both
proteins are found in the plasma membrane fraction,
thus allowing for a potential protein-protein interaction.
Given that both proteins are found in the plasma
membrane and possess similar patterns of staining, we
next sought to see if the pattern of staining observed
with phospho-PKCδ antibodies following FGF2 adminis-
tration was consistent with localization at Cx43 gap
junction plaques. Accordingly, we performed immuno-
fluorescent co-detection of both phospho-PKCδ
(Thr505) and Cx43. Cx43 is diffusely detected through-
out the cytoplasm with distinct areas of bright, punctate
fluorescence at the periphery of the cells, near cell-cell
borders (Figure 3i). PKCδ is primarily observed at the
nuclear compartment of these cells, though a similar
pattern of fluorescence accumulation in defined regions
at cell-cell borders is observed (Figure 3ii). When the
fluorescent images are merged, there is a distinct co-
detection of both PKCδ and Cx43 in punctate clusters
near cell-cell contacts, consistent with the expected pat-
tern of staining seen at gap junction plaques (Figure
3iv). Importantly, while this immunofluorescent
co-detection of PKCδ and Cx43 does not confirm any
protein-protein interaction, it provides critical feasibility
that the two proteins are located in situ in a manner
that could permit protein-protein interactions.
Co-immunoprecipitation of Cx43 and PKCδ
Next, we attempted to establish protein-protein interac-
tions between Cx43 and PKCδ by biochemical means.
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from whole cell extracts isolated from MC3T3 cells.
Previous studies have shown that PKCa and PKCε can
interact with Cx43 [22,23]. As a result, we used an anti-
panPKC antibody and an anti-PKCε antibody as controls
to ensure the efficacy of our co-immunoprecipitations.
First, we confirmed the specificity of the antibodies to
be used for co-immunoprecipitation experiments by
western blotting MC3T3 whole cell extracts (Figure 4A).
As expected, we detect the presence of PKCδ, PKCε and
Cx43 in MC3T3 cells. Additionally, the abundance of
these factors was not appreciably affected by treatment
of the cells for 15 minutes with FGF2 (5 ng/ml). Next,
we examined whether anti-Cx43 antibodies could be
used to co-immunoprecipitate PKC family members,
including PKCδ. Immunoprecipitations were performed
with non-immune IgG, anti-PKC or anti-Cx43 antibo-
dies, and western blots of supernatant (S) and bead (B)
Figure 1 Phosphorylation of Cx43 at serine 368 by PKCδ. (A). Western blots (n = 5) performed with anti-phospho-PKCδ (Thr505) and anti-
phospho-Cx43 (Ser368) antibodies show concomitant phosphorylation of PKCδ and Cx43 following treatment with 5 ng/ml FGF2 and 200 nM
PMA (positive control). (B). Western blots (n = 3) probed with anti-phospho-Cx43 (Ser368) antibodies reveal that the PKCδ inhibitor, rottlerin
(3 μM and 5 μM), can block the FGF2-induced phosphorylation of Cx43 at serine 368. Blots probed with anti-GAPDH antibodies are to verify
equal loading. Representative blots are shown. Mean densitometric values of the blots from all experiments are shown in the accompanying
bar graphs. Error bars indicate standard deviation. An asterisk denotes a p-value <0.05, relative to control.
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with anti-panPKC, anti-PKCδ and anti-PKCε specific
antibodies, as indicated in Figure 4B. In all cases, non-
immune IgG failed to immunoprecipitate PKCs. As
expected, anti-PKC isoform antibodies were able to
immunoprecipitate PKCs. Importantly, anti-Cx43 anti-
bodies were able to co-immunoprecipitate proteins
detectable with all three anti-PKC antibodies, supporting
a protein-protein interaction between PKCs (a, δ and ε)
and Cx43.
Next, we attempted the opposing co-immunoprecipi-
tation, using anti-PKC antibodies to co-immunoprecipi-
tate Cx43. Immunoprecipitations were performed with
non-immune IgG, anti-Cx43, or anti-PKC antibodies,
and western blots of supernatant (S) and bead (B) frac-
tions from the immunoprecipitations were probed with
anti-Cx43 specific antibodies, as indicated in Figure 4C.
Non-immune IgG failed to immunoprecipitate PKCs. As
expected, anti-Cx43 antibodies were able to
immunoprecipitate Cx43 protein. Antibodies against
panPKC, PKCδ and PKCε precipitate two products that
are detected with Cx43 antibodies, a ~43 kD and a ~46
kD protein. The ~43 kD protein is the non-phosphory-
lated (NP) form of Cx43, while the ~46 kD protein is a
phosphorylated form of Cx43 (p-Cx43). Interestingly,
it would appear that phosphorylated Cx43 (~46 kD)
is preferentially associated with all three PKCs, as
this is the principal product detected in the bead
fractions from co-immunoprecipitations with anti-PKC
antibodies (Figure 4C, lanes 5,7 and 9), in contrast to
the predominance of the ~43 kDa band (NP form) that
is observed in the Cx43 direct immunoprecipitation
(Figure 4C, lane 3).
To validate that this ~46 kD product corresponds to
phosphorylated Cx43, co-immunoprecipitations were
performed using non-immune IgG, anti-Cx43 and anti-
phospho-PKCδ antibodies, and the immunoprecipitated
products were probed by western blotting with anti-Cx43
Figure 2 FGF2 induces the accumulation of phospho-PKCδ in both the nuclei and plasma membrane.( A ) .S e r u ms t a r v e dM C 3 T 3c e l l s
were subjected to immunofluorescent detection with anti-phospho-PKCδ (Thr505) antibodies during a time course of treatment with FGF2
(5 ng/ml). Representative images collected by epi-fluorescence microscopy are shown for each time point. Small arrows indicate the punctate
staining at the cell periphery. The scale bar indicates ~10 μm. (B) Western blots (n = 3) probed with anti-PKCδ, anti-phospho-PKCδ (Thr505)
and anti-Cx43 antibodies were performed on equal amounts of plasma membrane protein extracts from FGF2 (5 ng/ml) treated osteoblasts.
Representative blots are shown.
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noticeable enrichment of the higher molecular weight
p r o d u c t( ~ 4 6k D a )i so b s e r v e di nt h ec o - i m m u n o -
precipitations of Cx43 with anti-PKC antibodies in com-
parison to the direct Cx43 immunoprecipitation.
(Figure 4D). In support of the notion that the 46 kDa
protein is a phosphorylated form of Cx43, the anti-
phospho-serine antibody strongly reacts with the
~46 kDa product in the co-immunoprecipitations with
anti-PKCδ antibodies (Figure 4D). These data reinforce
the hypothesis that PKCδ preferentially associates with
phospho-Cx43.
We have previously shown that PKCδ (but not PKCε)
translocates to the nucleus of FGF2 treated osteoblasts
by 30 minutes [14]. At intermediate time points follow-
ing FGF2 treatment, there is a distinct accumulation of
PKCδ in nodules at the plasma membrane, as shown in
Figures 2 and 3. To determine the kinetics of association
between Cx43 and PKCδ in FGF2 treated osteoblasts,
MC3T3 cells were treated with FGF2 for 0, 10 and 20
minutes. Whole cell extracts were immunoprecipitated
with non-immune IgG or anti-PKCδ antibodies and
western blots of supernatant (S) and bead (B) fractions
from the immunoprecipitations were probed with anti-
Cx43 antibodies, as shown in Figure 5. There is a dis-
tinct increase in the Cx43/PKCδ interaction following
10 minutes of exposure to FGF2 (~1.5 fold increase in
co-immunoprecipitated Cx43 versus input, relative to
untreated samples). This association is transient, how-
ever, as the Cx43/PKCδ interaction is reduced to below
basal levels by 20 minutes (~1.5 fold decrease in co-
immunoprecipitated Cx43 versus input, relative to
untreated samples). By 40 minutes of FGF2 treatment,
we are unable to co-precipitate Cx43 and PKCδ (data
not shown). This data is consistent with the kinetics of
cellular re-distribution of PKCδ following FGF2 treat-
ment, shown in Figure 2.
GST pulldown of PKCδ with the Cx43 C-terminal tail
Finally, in order to confirm that the association between
PKCδ and Cx43 occurs in the C-terminal domain of
Cx43, we performed GST-pulldown assays, using a
recombinant GST-Cx43 fusion protein that spans
amino acids 241-382 of the Cx43 C-terminal tail
Figure 3 Co-detection of Cx43 and phospho-PKCδ at the plasma membrane. Serum starved MC3T3 cells were treated with FGF2 for 10 min
prior to fixation and subsequent staining with (i) mouse anti-Cx43 (red), (ii) rabbit anti-phospho-PKCδ (Thr505) (green), (iii) DAPI (blue). A merged
image is also shown (iv). Arrows indicate the same position on each panel and correspond to areas where both Cx43 and phospho-PKCδ appear
to be closely co-detected in their respective panels. A representative field of view is shown. The white scale bar is ~10 μm.
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with the C-terminal tail of Cx43 because this domain
is commonly associated with the assembly of signal
complexes [15-18] and includes characterized PKC
phosphorylation sites [19].
Recombinant, purified GST-Cx43CT or GST-alone
were crosslinked to glutathione sepharose 4B beads. The
crosslinked beads were then used to pulldown interact-
ing proteins from MC3T3 whole cell extracts. The input
and bead fractions were then western blotted with anti-
PKCδ antibodies. GST-Cx43CT(241-382)-conjugated
beads could strongly pull down PKCδ from MC3T3
whole cell extracts (Figure 6). Beads conjugated to GST
alone were unable to pull down PKCδ. Specificity of the
GST-pulldown was confirmed by probing the western
blot with anti-GAPDH antibodies, which revealed an
immunoproduct in the input fr a c t i o nb u tn o ti ne i t h e r
bead fraction (data not shown).
Discussion
Previously, we have shown that modulation of Cx43
protein levels can affect the impact of FGF2 on
Figure 4 Connexin43 and PKCδ are present in a protein complex. (A). Whole cell extracts from cells treated with vehicle or 5 ng/ml FGF2
for 15 minutes were subjected to western blotting with the indicated antibodies (n = 3). (B). Whole cell extracts were immunoprecipitated (IP)
with non-immune IgG, anti-PKC (δ, pan or ε) or anti-Cx43 antibodies, as indicated. The supernatant (S) and bead (B) fractions from the
immunoprecipitations were subjected to western blotting (WB) with anti-PKC (δ, pan or ε) antibodies. Immunoprecipitation with anti-Cx43
antibodies co-precipitates PKCδ (as well as PKCε). (C). Whole cell extracts were immunoprecipitated with non-immune IgG, anti-Cx43, or anti-PKC
(pan, δ,o rε) antibodies, as indicated. The supernatant (S) and bead (B) fractions from the immunoprecipitations were subjected to western
blotting with Cx43 antibodies. All three anti-PKC antibodies co-precipitate Cx43. (D). Whole cell extracts were prepared from cells treated with
5 ng/ml FGF2 for 10 minutes. The extracts were immunoprecipitated with non-immune IgG, anti-Cx43, or anti-phospho-PKCδ (Thr505) antibodies,
as indicated. The bead fractions from the immunoprecipitations were subjected to western blotting with anti-Cx43 or anti-phospho-serine
antibodies. Anti-phospho-PKCδ (Thr505) antibodies preferentially co-immunoprecipitate serine phosphorylated Cx43.
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[14]. In that study, we reported that over expression of
Cx43 potentiates the transcriptional response to FGF2
by enhancing the activation and mobilization of PKCδ
in the cell, which ultimately increases transcription of
the osteoblast specific gene, osteocalcin. Conversely, we
show that inhibition of Cx43 expression or function
could inhibit the responsiveness of the osteocalcin gene
to FGF2 treatment. These data established the involve-
ment of Cx43 and PKCδ in the osteoblast response to
FGF2, however, it remained undetermined how the rela-
tive abundance of Cx43 could impact PKCδ function.
Several studies have shown that FGF2 can activate
PKCδ [24-29], or that FGF2 can increase phosphoryla-
tion of Cx43 [22,30,31]. Additionally, the activation of
PKC isoforms, by phorbol esters has been shown to
result in the inhibition of gap junctional communication
[19,32-35]. However, a physical interaction of PKCδ
with Cx43 has never been reported, nor has FGF2 been
shown to increase phosphorylation of Cx43 in a PKCδ-
dependent manner.
In this study, we demonstrate via immunofluorescence
staining and biochemical methods that PKCδ physically
interacts with Cx43. While alone, the immunofluores-
c e n c ed o e sn o tp r o v eap h y s i c a li n t e r a c t i o n ,w et h i n k
that this data provides strong support of the feasibility
of a physical interaction in situ and that the co-precipi-
tation studies are biologically relevant. We go on to
characterize the kinetics of the phosphorylation, interac-
tion and cellular translocation following FGF2 treat-
ment, revealing a transient association of PKCδ with
Cx43 at the plasma membrane and subsequent accumu-
lation of PKCδ in the nucleus following treatment with
FGF2. Our study is the first to show that PKCδ can phy-
sically interact with Cx43 in osteoblastic cells, and that
there is a PKCδ-dependent phosphorylation of Cx43 at
serine 368 that occurs in response to FGF2 administra-
tion. It is likely that multiple phosphorylations of Cx43
occur, in addition to the one detected at serine 368, as
phosphorylation of serine 368 alone is not sufficient to
result in the observed molecular weight shift of Cx43 on
SDS-PAGE gels to ~46 kDa [36-38].
Figure 5 FGF2 treatment promotes a transient increase in association of Cx43 and phospho-PKCδ. Whole cell extracts were prepared
from cells treated with vehicle or 5 ng/ml FGF2 for the indicated time. The extracts were immunoprecipitated (IP) with non-immune IgG, anti-
Cx43, or anti-phospho-PKCδ (Thr505) antibodies, as indicated. A fraction of the input and the bead fractions from the immunoprecipitations were
subjected to western blotting (WB) with anti-Cx43 antibodies. The co-precipitated Cx43 and phospho-PKCδ complex is most abundant at
10 minutes and returns to basal levels by 15 minutes. The graph reveals the average ratio of co-immunoprecipitated Cx43 relative to the Cx43
present in the input fraction for each time point from three separate experiments. Error bars indicate standard deviation. An asterisk denotes a
p-value <0.05, relative to control. The ratio for the 0 min FGF2 treatment point has been arbitrarily set to a value of 1.
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PKC family member, PKCε, has been reported following
FGF2 treatment in cardiomyocytes [22]. It is unclear
whether the involvement of PKCδ in the FGF2-response
and association with Cx43 also occurs in cardiomyo-
c y t e s ,o rw h e t h e rt h i si sa no s t eoblast-specific interac-
t i o n .I tw o u l dn o tb es u r p r i s i n gt h a tP K C δ could also
associate with Cx43 in cardiomyocytes, as FGF2, PKCε,
PKCδ and Cx43 have all been implicated in cardiopro-
tection following ischemia [39-43]. Notably, in a pre-
viously reported study in osteoblasts, we did not detect
a translocation of PKCε following FGF2 treatment in
these cells, suggesting distinct roles for PKCδ and PKCε
in the FGF2-response of bone forming cells [14].
In this study, we report that PKCδ physically interacts
with the C-terminal tail of Cx43. We speculate that the pre-
ferential interaction of PKCδ with the phosphorylated form
of Cx43 is because PKCδ directly phosphorylates Cx43 (i.e.,
Cx43 is a substrate for PKCδ). The fact that inhibition of
PKCδ activity with rottlerin can prevent phosphorylation of
Cx43 at serine 368 indicates that, at a minimum, PKCδ lies
upstream of Cx43 phosphorylation, and that Cx43 may be a
direct substrate for PKCδ. Alternately, it is possible that the
phosphorylation of Cx43 is a prerequisite for the docking of
PKCδ with the Cx43 C-terminal tail. Future studies will
explore these alternatives. It should also be noted that,
while commonly used as an inhibitor of PKCδ, the specifi-
city of rottlerin has been questioned [44].
Figure 6 PKCδ associates with the C-terminal tail of Cx43. GST pull downs were performed using GST- or GST-Cx43CT(241-381) crosslinked
beads and whole cell extracts from MC3T3 cells. The input, and bead fractions were analyzed by western blot. The blots were probed with anti-
PKCδ antibodies. PKCδ is pulled down by the GST-Cx43CT(241-381) construct but not by GST-crosslinked beads alone. Mean densitometric values
of the blots are shown in the accompanying bar graph. The graph reveals the ratio of “pulled-down” PKCδ relative to the PKCδ present in the
input fraction from three separate experiments. Error bars indicate standard deviation. An asterisk denotes a p-value <0.05, relative to control.
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affects osteoblast function by regulating signal transduc-
tion cascades. We predict that intercellular communica-
tion via gap junctions results in the sharing of signals/
second messengers among coupled osteoblasts, permit-
ting cells to respond more robustly to extracellular sti-
muli, such as growth factors, hormonal signals or
mechanical load. Central to this model is the concept
that Cx43 serves as a docking platform for signaling
complexes, recruiting them to the gap junction plaque
where they can respond to transmitted signals/second
messengers. Previously, we had identified PKCδ as a
mediator of the Cx43 enhanced response of osteoblast
to FGF2 but, it was unknown whether or not PKCδ was
recruited to the Cx43 gap junction plaque to participate
in signaling [14]. Now, we can add PKCδ to the growing
number of signaling complexes that are recruited to and
participate in signaling at the gap junction plaque.
By establishing the protein-protein interactions that
can occur between gap junctions and signaling com-
plexes, we gain valuable insights into the molecular
mechanisms by which gap junctions/connexins can
affect cellular signaling to ultimately affect cell function.
Additionally, we learn how gap junctions themselves
may be regulated. Indeed, phosphorylation of Cx43 can
affect its function/transport, including assembly of hemi-
channels, transport to the plasma membrane, channel
gating and turnover [36,45]. Furthermore, the clarifica-
tion of these interactions lends insights into the biologi-
cally relevant molecules that may be propagated through
gap junction channels. The activation of several signal-
ing cascades downstream of the FGF2-FGF receptor
complex generates second messengers that may trans-
verse the gap junction channel. Among the signal cas-
cades activated by the FGF2-FGF receptor complex
include Ras-ERK MAPK cascade, phospholipase Cg,
phospholipase D and cytosolic phospholipase A2, which
produce second messengers like inositol phosphate deri-
vates, diacylglycerol, arachidonic acid, and calcium
[46-52]. Of note, several of these second messengers
have been shown to regulate PKCδ activation [21,53-56].
Importantly, it is equally plausible that the role of
Cx43 in FGF-signaling is independent of its function as
a permeable pore for direct cell-cell communications.
Connexins have been widely implicated as functioning
as unpaired hemichannels [57]. Furthermore, several
studies have revealed important non-channel roles for
connexins in cell function [58,59]. For example, it is
possible that Cx43 may affect FGF2-initiated signaling
cascades and osteoblast function by sequestering signal
complexes to cellular microdomains, altering mitochon-
drial function, direct nuclear shuttling or affecting signal
complex turnover, independent of cell-cell
communication.
Future studies are needed to define the need for PKCδ
protein docking with the Cx43 gap junction channel.
More specifically, if the proximal recruitment of PKCδ
to the Cx43-dependent “shared” messenger is required
to transmit the amplification of the FGF2 response
among osteoblasts. By studying the mechanism of action
of gap junctions in transmitting signals among the cells
of bone, we hope to be able to understand the role of
gap junctions in how skeletal cells coordinate function
during bone growth, remodeling and repair.
Conclusion
Cx43 can serve as a direct docking platform for the
recruitment of PKCδ in order to affect FGF2 signaling
in osteoblasts. PKCδ is found to transiently associate
with Cx43 at cell-cell junctions, following stimulation
with FGF2. Subsequently, PKCδ accumulates in the
n u c l e u s ,w h e r ew eh a v es h o w ni nap r e v i o u ss t u d yt h a t
it alters transcription of key osteoblastic genes [14].
These data expand the list of signal molecules that
assemble on the Cx43 C-terminal tail and provide a cri-
tical context to understand how gap junctions modify
signal transduction cascades in order to impact cell
function.
Methods
Chemicals, Antibodies and Reagents
Unless specified, chemicals were purchased from Sigma
(St Louis, MO). Recombinant FGF2 was from R&D Sys-
tems (Minneapolis, MN). FGF2 was reconstituted in a
sterile vehicle solution (phosphate buffered saline, 0.1%
bovine serum albumin, 1 mM dithiothreitol). The
sources of antibodies used were Sigma (rabbit anti-Cx43
(#C6219) and mouse anti-phospho-serine (#P5747) anti-
bodies), Santa Cruz Biotechnology (Santa Cruz, CA; rab-
bit anti-panPKC (#sc-10800), rabbit anti-PKCε (#sc-214)
and rabbit anti-PKCδ antibodies (#sc-937)), Cell Signal-
ing Technology (Beverly, MA; rabbit anti-phospho-Cx43
(Ser 368) (#3511) and rabbit anti-phospho-PKCδ
(Thr505) (#9374), and Chemicon (Temecula, CA; mouse
anti-Cx43 (#MAB3067), anti-GAPDH (#MAB374); and
Millipore (Billerica, MA) FITC-conjugated donkey anti-
rabbit IgG (#AP182F), Cy3-conjugated donkey anti-
mouse IgG antibodies(#AP192C). The following reagents
were also used: DAPI (4’,6-Diamidine-2’-phenylindole
dihydrochloride; Roche, Indianapolis, IN), Protein G
PLUS/Protein A-Agarose beads (Calbiochem, La Jolla,
CA), non-immune mouse and rabbit IgG antibodies
(Calbiochem, San Diego, CA).
Cell Culture and FGF2 Treatments
MC3T3-E1 (clone 4) osteoblasts were purchased from
the ATCC (Manassas, VA). These cells were cultured in
DMEM (Cellgro, Herndon, VA) supplemented with 10%
Niger et al. BMC Biochemistry 2010, 11:14
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lin (50 IU/ml)-streptomycin (50 μg/ml) solution (Cell-
gro) as described previously [14]. For experiments with
FGF2 treatment, cells were serum-starved in DMEM
containing 0.1% fetal bovine serum and 0.3% bovine
s e r u ma l b u m i nf o r2 4h o u r s .F G F 2w a sa d d e dt ot h e
starvation media at 5 ng/ml. The vehicle diluent for
FGF2 (phosphate buffered saline, 0.1% bovine serum
albumin, 1 mM dithiothreitol) was used as a negative
control for FGF2 treatments. Cell viability was routinely
monitored using a CCK-8 assay (Alexis Biochemicals,
Farmingdale, NY). Cell viability was unaffected by FGF2
or inhibitor treatments when compared to vehicle trea-
ted cells. All experiments performed in this study were
repeated at least three times, and data from representa-
tive experiments are shown.
Western Blotting
Whole cell extracts were prepared from confluent cul-
tures of MC3T3 cells using a modified RIPA buffer (50
m MT r i s ,p H8 . 0 ,1 5 0m MN a C l ,1 0m Ms o d i u mp y r o -
phosphate, 10 mM sodium fluoride, 10 mM b-glycero-
p h o s p h a t e ,1m ME G T A ,1m ME D T A ,2m Ms o d i u m
vanadate, 1% NP-40, 0.5% sodium deoxycholate, 0.1%
sodium dodecyl sulfate, and 1× protease inhibitor cock-
tail (Sigma)). For western blots using plasma membrane
extracts, plasma membrane fractions were obtained and
partially purified using a modified sucrose density gradi-
ent method [60]. Briefly, FGF2-treated MC3T3 cells
from trypsinized cultures were centrifuged at 900 g at
4°C for 5 minutes and the resulting cell pellets were
washed twice in cold HBSS (Cellgro). Cells were resus-
pended in cold hypotonic buffer (10 mM HEPES, pH
7.9, 1.5 mM MgCl2, 10 mM KCl, 0.5 mM DTT) with 1×
protease inhibitor cocktail and 1 mM sodium orthova-
nadate, and incubated on ice for 10 min to allow swel-
ling. Cells were then lysed by adding 1% NP-40. The
resulting lysates were centrifuged (1300 g, 10 min., 4°C)
to remove unbroken cells and nuclei. The supernatants
were then loaded on top of sucrose gradients generated
by layering a 10% sucrose (w/v) solution on top of a
60% sucrose solution. Following centrifugation (45,500 g,
30 min., 4°C) enriched plasma membrane fractions were
collected in between the 10% and 60% sucrose layers and
stored at -80°C until needed. For all western blots, equal
amounts of proteins were electrophoresed on 10% SDS-
PAGE gels, blotted to PVDF membranes and probed
with the indicated antibodies. Membranes were stripped
and re-probed with GAPDH antibodies to ensure equal
loading of proteins among lanes. All blots were repeated
at least three times with independent cell cultures. Repre-
sentative data are shown for each. Where indicated, the
band intensites of western blots were quantitated
with ImageJ image analysis software (NIH, Bethesda,
MD). Data from multiple blots (a minimum of three)
were normalized and averaged. Statistical significance
was determined by one-way ANOVA and Tukey’sp o s t
hoc test. A p-value of <0.05 was used as an indication of
statistical significance.
Immunofluorescence
Cells grown to confluence on coverslips in 6-well plates
were prepared for immunostaining, following FGF2
treatments for the indicated time. Samples were stained
and imaged as previously described [14]. Staining using
non-immune rabbit and mouse IgG and anti-rabbit
FITC and anti-mouse Cy3 secondary antibodies were
used as a negative control. All immunostaining experi-
ments were performed on a minimum of two coverslips
per experiment and repeated on at least three separate
cultures. Up to four fields of view were imaged per cov-
erslip. Representative images are shown for each
experiment.
Co-immunoprecipitations
MC3T3 cells were harvested with IP buffer (50 mM Tris
pH 8.0, 150 mM NaCl, 1.0% Triton-×-100, 10 mM sodium
pyrophosphate, 10 mM a-glycerophosphate, 10 mM
sodium fluoride, 1 mM EDTA, 1 mM EGTA, 1 mM
sodium orthovanadate and 1× proteases inhibitor cocktail).
Whole cell lysates (500 μg total proteins) were pre-cleared
with protein A/G agarose beads at 4°C for 60 minutes.
The cleared supernatants were incubated overnight at 4°C
with 2 μg of the indicated antibodies, followed by a
one-hour incubation at 4°C with protein A/G-agarose
beads. After five washes in iced cold-PBS, the protein
were eluted from the beads by heating the samples for
5 minutes at 95°C in Laemmli SDS buffer (62.5 mM Tris-
HCl, 2%w/v SDS, 10% glycerol, 50 mM DTT, 0.01% w/v
bromophenol blue). A fraction of the eluted proteins
(bead fraction) and supernatant (supe fraction) were then
analyzed by western blotting (as described above) with the
indicated antibodies.
Glutathione-S-Transferase (GST) Pulldowns
The region of the GJA1 gene corresponding to the C-
terminal tail of the Cx43 protein (amino acids 241-382)
were PCR amplified with the following forward and
reverse primers: mCx43-EcoR1-241-Forward,
GGAATTCCGTCTTCTTCAAGGGCGTT and mCx43-
XhoI-382-Reverse, CCGCTCGAGTTAAATCTC-
CAGGTCAGG. The gel purified Cx43 C-terminal tail
PCR product was then subcloned into the EcoR1/XhoI
sites of the pGEX-5X-2 vector (Amersham, Piscataway,
NJ) in-frame with an N-terminal GST tag. The resultant
pGEX-Cx43CT (241-382) construct was used to gener-
ate purified GST-Cx43CT(241-382) protein, as we have
published previously [61]. Empty pGEX-5X-2 vector was
Niger et al. BMC Biochemistry 2010, 11:14
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Page 10 of 12used to generate GST alone, to be used as a negative
control. Equal amounts of purified GST- or GST-
Cx43CT(241-382) protein were covalently crosslinked to
Glutathione Sepharose 4B beads (Amersham) with
dimethyl pimelimidate. Immobilized GST- or GST-
Cx43CT (241-382) beads (25 μl) were incubated with
100 μg of MC3T3 whole cell extracts for 4 hours at 4°C.
After being washed five times in pulldown buffer (50
mM HEPES, pH 7.5, 1 mM EDTA, 150 mM NaCl, 10%
glycerol, 0.1% Tween-20, 0.5 mM DTT, protease inhibi-
tor cocktail), the bound proteins were eluted and ana-
lyzed by western blotting.
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